Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ENROLLING BY INVITATION
NCT07135219
EARLY_PHASE1

A Study of Cizutamig in Patients With Immunoglobulin A Nephropathy

Sponsor: Peking University First Hospital

View on ClinicalTrials.gov

Summary

The purpose of this study is to assess the safety, tolerability, PK, PD, immunogenicity, and preliminary clinical activity of cizutamig in patients with IgAN.

Official title: An Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Clinical Activity of Cizutamig in Patients With Immunoglobulin A Nephropathy

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

15

Start Date

2025-07-16

Completion Date

2027-01

Last Updated

2025-08-22

Healthy Volunteers

No

Interventions

DRUG

Biological: cizutamig

Cizutamig will be dosed according to the protocol.

Locations (1)

Peking University First Hospital

Beijing, China